1071-P: Impact of the GluCare Health Model of Care in Diabetics with NAFLD as Measured Using Shear Wave Ultrasound—A Three-Month Outcomes Study

Abstract

Introduction: Type 2 diabetes (T2D) and obesity are risk factors for nonalcoholic fatty liver disease (NAFLD). Newer and non-invasive imaging techniques of transient elastography and shear wave elastography provide the opportunity to measure liver stiffness (1). Shear Wave Ultrasound (SWU) is a non-invasive imaging technique that has been increasingly used in the management of patients with diabetes (2). Continuous monitoring and engagement approach, such as the one utilized by GluCare.health, has been proven to effectively improve metabolic conditions associated with diabetes in trials (3). This integrated care model uses data-driven personalization of interventions to increase patient's access and engagement with health provider to surpass outcomes of traditional care methods (4). Methods: Retrospective review of medical records of 47 patients, evaluated at GluCare (Dubai, UAE), from 18 to 70 years old with T2D and body mass index (BMI) over 25. All the patients were under anti diabetic drugs. BMI and data from a SWU model FT100 were collected and compared between the first visit and after 3 months GluCare.health intervention. Correlations between 3-month changes in BMI, liver ultrasound attenuation parameter (UAP) and stiffness were explored using statistical analysis. Results: Average changes in BMI over the first three months of treatment were statistically significant (p<0.001). The average UAP decrease was significant at 10 % level (p=0.086) and every unit decreased in BMI was associated with 7.23 dB/m reduction in UAP (p<0.05). The average change in liver stiffness was not statistically significant (p>0.1). The analysis also found a significant correlation between changes in BMI and stiffness at the 5% significance level, with a moderately strong correlation (r=0.38). Conclusion: The study suggests that the GluCare.Health intervention may be effective in reducing BMI in patients with diabetes, and it may also have some effect on NAFLD. Disclosure M. Caccelli: None. Y. Said: None. S. Aleabova: None. C. Palsky: None. A. Hashemi: None. I. Almarzooqi: None.